Modafinil for attentional and psychomotor dysfunction in advanced cancer: a double-blind, randomised, cross-over trial
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Cognitive impairment seems to be highly prevalent in patients with advanced cancer. Modafinil, a novel vigilance and wake-promoting agent, may be an alternative treatment. We wanted to investigate this treatment on attentional and psychomotor dysfunction in cancer patients. 28 cancer patients with a tiredness score of 50 mm or more on a scale of 0 to 10 (0=no tiredness, 10=worst possible tiredness) and Karnofsky Performance Status 40—70 were included. All medications were kept stable during the trial despite short acting opioids for breakthrough pain. On day 1 the patients were randomly assigned to receive 200 mg Modafinil orally or placebo and on day 4 they crossed-over to the alternative treatment. Finger Tapping Test (FTT), Trail Making Test (TMT) and Edmonton Symptom Assessment System (ESAS) were evaluated before tablet intake and again 4, 5 hours after. FTT for the dominant hand as well as TMT were statistically significantly improved on modafinil (p-values=0.006 and 0.042, respectively). On ESAS, depression and drowsiness also improved statistically significantly (p-values=<0.001 and 0.038, respectively). Modafinil in a single dose regimen was significantly superior to placebo regarding two cognitive tests of psychomotor speed and attention. Furthermore subjective scores of depression and drowsiness were significantly improved by modafinil.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The prevalence of psychiatric disorders among cancer patients
Derogatis, L. R. (1983) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1983.03330300035030 · Cited by 1,575
A Prospective Trial of Modafinil as an Adjunctive Treatment of Major Depression
DeBattista, C., Lembke, A., Solvason, H. B., Ghebremichael, R., & Poirier, J. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000104910.75206.b9 · Cited by 144 · cited 1×
“Likewise, modafinil seems to have these effects, which are of great importance for patients in palliative care, as they cannot await weeks or months for the slow onset of the traditional antidepressants.(14,52,53) Depression is frequently met in cancer patients in palliative care(41); however, the role of modafinil an…”
Background
Cited by
Prevalence, mechanisms, and management of cancer-related cognitive impairment
Janelsins, M. C., Kesler, S. R., Ahles, T. A., & Morrow, G. R. (2014) · International Review of Psychiatry · doi:10.3109/09540261.2013.864260 · Cited by 745
Cancer- and Cancer Treatment–Associated Cognitive Change: An Update on the State of the Science
Ahles, T. A., Root, J. C., & Ryan, E. L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.0116 · Cited by 704
Cognitive Effects of Cancer and Cancer Treatments
Ahles, T. A., & Root, J. C. (2018) · Annual Review of Clinical Psychology · doi:10.1146/annurev-clinpsy-050817-084903 · Cited by 367
Evidence‐based treatment of depression in patients with cancer
Li, M., Fitzgerald, P., & Rodin, G. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.7372 · Cited by 236
Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., & Wefel, J. S. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0723-1 · Cited by 161
“Furthermore, the efficacy of both MPH and MOD for improving cognitive function in this population has also received attention from researchers [24–30].”
Background
Metadata
- Authors
- Lundorff, L., Jønsson, B., & Sjøgren, P.
- Venue
- Palliative Medicine
- Publisher
- SAGE Publications
- Published
- 2009-07-31
- Volume
- 23
- Issue
- 8
- Pages
- 731-738
- ISSN
- 0269-2163 (ISSN-L)
- 1477-030X
- OpenAlex
- W2018459614
- Cited by
- 106
- References
- 2
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.